After more than ten months of concerted efforts from all parties involved, we have completed the enrollment, administration, and three-month follow-up for 10 patients with RP-ILD. RP-ILD is a clinically highly fatal pulmonary disease, often referred to as "the tumor among lung diseases." Typically, the likelihood of death within two weeks after diagnosis is extremely high, with a mortality rate of 70–90% within 3-6 months according to clinical statistics. Remarkably, all 10 enrolled patients who received treatment were discharged approximately two weeks after administration and remained stable during the subsequent three follow-ups over three months, with no need for rehospitalization. Our precisely defined exosome subpopulation demonstrated astonishing clinical efficacy. Furthermore, no adverse clinical reactions were observed in any of the 10 patients.